Table 1.
Microglia specificity of AAV vectors in different brain regions.
| AAV construct | Cerebral cortex | Striatum | Cerebellum | n | |
|---|---|---|---|---|---|
| Promoter | miR target | ||||
| PGK | miR-9.T | 12.0 ± 3.7 (319/2656) | 7.4 ± 3.4 (191/2576) | 34.4 ± 10.8 (901/2620) | 5 |
| Iba1 | – | 2.1 ± 1.3* (59/2791) | 68.8 ± 9.6** (1808/2628) | 85.7 ± 5.5 (2244/2618) | 5 |
| Iba1 | miR-9.T | 27.3 ± 2.4**† (753/2760) | 94.0 ± 2.0**† (2663/2833) | 100 ± 0*** (2726/2726) | 5 |
| Iba1 | miR-9.T miR-129-2-3p.T | 86.5 ± 5.6**†‡ (2750/3180) | 99.6 ± 0.5**† (3127/3140) | 100 ± 0*** (2712/2712) | 5 |
Data are presented as mean ± s.d. (%). Numbers in parentheses indicate the number of cells counted (GFP- and Iba1-positive cells/GFP-positive cells). Comparison of microglial specificity between AAV groups one week after the injection was assessed as follows: cerebral cortex, one-way ANOVA: F(3,16) = 540.425, P < 0.001; Bonferroni post hoc analysis: *P = 0.003, **P ≤ 0.001 for vs. PGK.miR-9.T, †P ≤ 0.001 for vs. Iba1, ‡P ≤ 0.001 for vs. Iba1.miR-9.T; striatum, one-way ANOVA: F(3,16) = 330.221, P < 0.001; Bonferroni post hoc analysis: **P ≤ 0.001 for vs. PGK.miR-9.T, †P ≤ 0.001 for vs. Iba1; cerebellum, Kruskal–Wallis test, Kruskal–Wallis statistic = 18.348, P < 0.001; post hoc Dunn’s analysis with Bonferroni adjustment for multiple comparisons: ***P = 0.002 for vs. PGK.miR-9.T. AAV adeno-associated virus, Iba1 ionized calcium-binding adapter 1, miR microRNA, n number of mice per group, PGK phosphoglycerate kinase 1.